Key facts
- This page summarizes Eiry Roberts's Form 4 filing for AMICUS THERAPEUTICS, INC. (FOLD).
- 6 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 27 Apr 2026, 16:41.
Eiry Roberts - 27 Apr 2026 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)
- Reporting relationship
- Director
- Issuer ticker
- FOLD
- Reported as of
- 27 Apr 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Apr 2026, 16:41:52 UTC
- Prior SEC filing
- 06 Jun 2025
- Next SEC filing
- 20 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christian Formica, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eiry Roberts filed Form 4 for AMICUS THERAPEUTICS, INC. (FOLD) on 27 Apr 2026.
Change
- Previous filing in this sequence was filed on 06 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001727606
Primary reporting owner
ROBERTS EIRY
- Relationship
- Director
- Address
- 47 HULFISH STREET, PRINCETON
- Signature
- /s/ Christian Formica, Attorney-in-Fact
- Signature date
- 27 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FOLD
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -76,275
- Change %
- -100%
- Price
- $14.50*
- Shares after
- 0
- Date
- 27 Apr 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FOLD
transaction
Derivative
Stock Options (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -40,625
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,625
- Exercise price
- $10.71
- Footnotes
- F2, F3
FOLD
transaction
Derivative
Stock Options (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -45,423
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 45,423
- Exercise price
- $8.55
- Footnotes
- F2, F3
FOLD
transaction
Derivative
Stock Options (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -30,474
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,474
- Exercise price
- $12.62
- Footnotes
- F2, F3
FOLD
transaction
Derivative
Stock Options (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -42,467
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,467
- Exercise price
- $10.27
- Footnotes
- F2, F3
FOLD
transaction
Derivative
Stock Options (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -74,872
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 74,872
- Exercise price
- $5.96
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Eiry Roberts is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
Footnote F2
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
Footnote F3
Each Option was fully vested.
Footnote F4
Each Option vested in full in connection with consummation of the Merger.